Neurocrine Biosciences’ (NBIX) recent pipeline wins are a nice way to end the year, notes Wedbush’s Laura Chico. She discusses the outlook for biotech stocks ahead of 3Q earnings. Wedbush has an outperform rating and a $137 price target on NBIX. She then looks at Travere Therapeutics (TVTX). She highlights that while shares continue to trade in the $7/share range, we see a compelling entry point at the present. She also talks about Ardelyx (ARDX) which she says that its improving gross/net discount could also provide a tailwind as we wait the Xphozah launch commencement in November. Additionally, she mentions that Wedbush is looking for a slight 3Q revenue miss for Biogen (BIIB). Tune in to find out more about the stock market today.
Market On Close
24 Oct 2023
SHARE
The Watch List
02 Feb 2024
Morning Trade Live
29 Feb 2024
The Watch List
05 Mar 2024
Morning Trade Live
07 Mar 2024
Market On Close
30 Jan 2024
The Watch List
24 Apr 2024